Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;51(2):578-84.
doi: 10.1128/JCM.02452-12. Epub 2012 Dec 12.

HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system

Affiliations

HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system

Moussa Thiam et al. J Clin Microbiol. 2013 Feb.

Abstract

In this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Maximum-likelihood tree depicting the phylogenetic relationships between the sequences in this study. The tree was constructed as indicated in Materials and Methods. aLRT statistics were used to support the tree topology and are indicated on the main branches. The letter Ψ indicates a very probable transmission chain between two sequences collected from one man and one woman. Asterisks indicate unique recombinant strains. HIV-1 reference sequences from the Los Alamos database are indicated by dashed lines, and sequences from the present study are indicated by solid lines.

References

    1. Diop-Ndiaye H, Toure-Kane C, Leye N, Ngom-Gueye NF, Montavon C, Peeters M, Mboup S. 2010. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res. Hum. Retroviruses 26:1133–1138 - PubMed
    1. Toure-Kane C, Montavon C, Faye MA, Gueye PM, Sow PS, Ndoye I, Gaye-Diallo A, Delaporte E, Peeters M, Mboup S. 2000. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res. Hum. Retroviruses 16:603–609 - PubMed
    1. Hamel DJ, Sankalé JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ. 2007. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res. Hum. Retroviruses 23:1189–1196 - PubMed
    1. Ndiaye HD, Toure-Kane C, Vidal N, Niama FR, Niang-Diallo PA, Dièye T, Gaye-Diallo A, Wade AS, Peeters M, Mboup S. 2009. Surprisingly high prevalence of subtype C and specific HIV-1 subtype/CRF distribution in men having sex with men in Senegal. J. Acquir. Immune Defic. Syndr. 52:249–252 - PubMed
    1. Tournoud M, Etard JF, Ecochard R, DeGruttola V. 2010. Adherence to antiretroviral therapy, virological response, and time to resistance in the Dakar cohort. Stat. Med. 29:14–32 - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data